Dr. Ayman Salah Al-hakim, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 747 S. 8th Street, Suite C, Griffin, GA 30224 Phone: 770-228-1767 Fax: 770-228-7562 |
Dr. Rao S. Moravineni, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 747 South 8th Street, Suite C, Griffin, GA 30224 Phone: 770-228-1767 Fax: 770-228-7562 |
Pravin Chimanlal Mehta, MD Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 230d W College St, Griffin, GA 30224 Phone: 770-229-6007 Fax: 770-229-1518 |
News Archive
Orthovita, Inc., an orthobiologics and biosurgery company, is pleased to announce that Dr. Pierce D. Nunley, Director of the Spine Institute of Louisiana, will present his abstract, "A Comparison of Clinical Outcomes and Adjacent Level Fractures in Patients Receiving Vertebroplasty for Osteoporotic Compression Fractures Using CortossTM or PMMA: A Prospective, Randomized Trial," at the 2009 Annual Meeting of the Congress of Neurological Surgeons (CNS).
Cyberonics, Inc., a global leader in epilepsy management, today announced results for the quarter ended January 28, 2011.
An international team of researchers led by infectious disease experts at the University of Georgia has received $5.2 million from the National Institutes of Health to develop a more accurate, affordable diagnostic test for Chagas disease, a parasitic infection that kills more than 50,000 people each year in Central and South America.
A dead crow and two pools of mosquitoes collected in DuPage County have been identified with West Nile virus, the first positive test results in Illinois this year for the mosquito-borne disease, Dr. Eric E. Whitaker, state public health director, today announced.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.
› Verified 1 days ago